Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372303 | 0.97 | SIGMAR1 (0.36) | SIGMAR1CARM1PRMT6PRMT8ATM | |
| Hydrochloric Acid SCHEMBL20474339 | 0.97 | ATM (0.36) | SIGMAR1CARM1PRMT6PRMT8ATM | |
| SCHEMBL522905 | 0.88 | ALOX15 (0.32) | — | |
| SCHEMBL3554595 | 0.80 | — | — | |
| SCHEMBL18426938 | 0.79 | MAPT (0.36) | TSHRALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL861779 | 0.79 | HTT (0.39) | SIGMAR1PRMT6LMNATDP1ALDH1A1 | |
| SCHEMBL23277739 | 0.77 | GRIN2D (0.31) | — | |
| SCHEMBL862113 | 0.77 | SMN1; SMN2 (0.41) | SIGMAR1TSHRALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3919857 | 0.77 | SIGMAR1 (0.38) | SIGMAR1LMNATDP1HRH3ALDH1A1 | |
| SCHEMBL5239083 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150252047-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-10 | — | — | US | claimed |
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | US | claimed |
| EP-1963320-A1 | PYRROLOPYRIDINE KINASE INHIBITING COMPOUNDS | OSI Pharmaceuticals, Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| EP-1797054-A2 | ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS | OSI Pharmaceuticals, Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| WO-2007067537-A1 | PYRROLOPYRIDINE KINASE INHIBITING COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | claimed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | claimed |
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006017443-A2 | ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20250074866-A1 | MODIFIED AMINE LIPIDS | INTELLIA THERAPEUTICS, INC. | 2025-03-06 | — | — | US | disclosed |
| CN-119285480-A | Modified amine lipids | 英特利亚治疗股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-12077483-B2 | Modified amine lipids | INTELLIA THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| EP-3560499-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20050014761-A1 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | 2005-01-20 | — | — | US | disclosed |
| US-20050014760-A1 | Methods of treating diseases or conditions using dihydropteridinone compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-20 | — | — | US | disclosed |
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
| EP-0656353-B1 | Aminochinoline derivates useful in the treatment of malaria | HOFFMANN LA ROCHE (CH) | 1998-06-03 | — | — | EP | disclosed |
| US-5596002-A | TREATMENT OF ANTIBIOTIC RESISTANT MICROORGANISMS | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0656353-A1 | Aminochinoline derivates useful in the treatment of malaria | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | QDPR, DHPS, DRD5 | SIGMAR1 1676/4885CARM1 4559/4885PRMT6 2358/4885 |
| US-20050014760-A1 | Methods of treating diseases or conditions using dihydropteridinone compounds | QDPR, DHPS, DHFR | SIGMAR1 3548/4885CARM1 4207/4885PRMT6 903/4885 |
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | BMX, ERBB2, FRK | SIGMAR1 3846/4885CARM1 641/4885PRMT6 585/4885 |
| US-20050014761-A1 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions | QDPR, DHPS, DHODH | SIGMAR1 3131/4885CARM1 4399/4885PRMT6 1195/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | SIGMAR1 1021/4885CARM1 2202/4885PRMT6 3185/4885 |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | BMX, ERBB2, FRK | SIGMAR1 3650/4885CARM1 724/4885PRMT6 882/4885 |
| US-12077483-B2 | Modified amine lipids | PHOSPHO1, SGMS1, SGMS2 | SIGMAR1 1663/4885CARM1 419/4885PRMT6 443/4885 |
| US-20250074866-A1 | MODIFIED AMINE LIPIDS | PHOSPHO1, SGMS1, SGMS2 | SIGMAR1 1663/4885CARM1 419/4885PRMT6 443/4885 |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | SIGMAR1 686/4885CARM1 3545/4885PRMT6 2118/4885 |
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | CCND2, ARG2, ARG1 | SIGMAR1 4266/4885CARM1 2757/4885PRMT6 822/4885 |
| US-20150252047-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | CCND2, CCND1, CCNA1 | SIGMAR1 4686/4885CARM1 1859/4885PRMT6 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.